• Friday, Sep 25, 2020
  • Last Update : 07:39 pm

Is the Russian vaccine a country-wide experiment?

  • Published at 09:45 pm August 11th, 2020
Is the Russian vaccine a country wide experiment
File photo: A scientist works inside a laboratory of the Gamaleya Research Institute of Epidemiology and Microbiology during the production and laboratory testing of a vaccine against the Covid-19, in Moscow on August 6, 2020 Reuters

Experts say without a full trial, the vaccine is hard to trust

An announcement by Russia on Tuesday that it will approve a Covid-19 vaccine after less than two months of human testing prompted alarm among global health experts, who said that with no full trial data, the vaccine is hard to trust.

Intent on being first in the global race to develop a vaccine against the pandemic disease, Russia has yet to conduct large-scale trials of the shot that would produce data to show whether it works - something immunologists and infectious disease experts say could be a "reckless" step.

"Russia is essentially conducting a large population level experiment," said Ayfer Ali, a specialist in drug research at Britain's Warwick Business School.


Alos Read - Indonesia starts human trials of China-made virus vaccine


She said such a super-fast approval could mean that potential adverse effects of a vaccine may not be picked up. These, while likely to be rare, could be serious, she warned.

Russian President Vladimir Putin said the vaccine, developed by Moscow's Gamaleya Institute, was safe and that it had been administered to one of his daughters.

"I know that it works quite effectively, forms strong immunity, and I repeat, it has passed all the needed checks," Putin said on state television.

Francois Balloux, an expert at University College London's Genetics Institute, said it was "a reckless and foolish decision".

"Mass vaccination with an improperly tested vaccine is unethical," he said. "Any problem with the Russian vaccination campaign would be disastrous both through its negative effects on health, but also because it would further set back the acceptance of vaccines in the population.”

Scientific papers

His comments were echoed by Danny Altmann, a professor of Immunology at Imperial College London, who said the "collateral damage" from deploying any vaccine that is not yet known to be safe and effective "would exacerbate our current problems insurmountably."

Even as Russia declared victory, more than half a dozen drugmakers around the world are in the process of conducting large-scale, advanced human trials of their potential Covid-19 vaccines, each with tens of thousands of volunteer participants.

Several of these frontrunners, including Moderna, Pfizer and AstraZeneca, say they hope to know if their vaccines work and are safe by the end of this year.

All are expected to publish their trial results and safety data and submit them to regulators in the United States, Europe and elsewhere for scrutiny before any licence could be granted.

The Russian vaccine's approval by the Health Ministry comes before trials that would normally involve thousands of participants, commonly known as a Phase III trial. Such trials are usually considered essential precursors for a vaccine to secure regulatory approval.


Alos Read - Putin: Russia has developed 'first' coronavirus vaccine


Peter Kremsner, an expert at Germany's University Hospital in Tuebingen who is working on clinical trials of a vaccine candidate from CureVac, said Russia's move was "reckless."

"Normally you need a large number of people to be tested before you approve a vaccine," he said. "I think it's reckless to do that if lots of people haven't already been tested."

Experts said the lack of published data on Russia's vaccine - including how it is made and details on safety, immune response and whether can prevent Covid-19 infection - leaves scientists, health authorities and the public in the dark.

"It is not possible to know if the Russian vaccine has been shown to be effective without submission of scientific papers for analysis," said Keith Neal, a specialist in the epidemiology of infectious diseases at Britain's Nottingham University.

51
51
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail